Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma

Leukemia volume 30, pages 844–853 (2016)Cite this article

Subjects

Abstract

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)—a subtype of Hodgkin lymphoma (HL)—is characterized by a low content of tumor cells, the lymphocyte predominant (LP) cells. Transformation into diffuse large B-cell lymphoma (DLBCL) occurs in about 10% of patients. We performed whole-genome mutation analysis of the DLBCL components from two composite lymphomas consisting of clonally related NLPHL and DLBCL as a means to identify candidate tumor suppressor genes and oncogenes in NLPHL. The analysis of LP cells for selected mutations of the DLBCL revealed that most mutations are also present in the LP cells, indicating a close relationship between the two components. The analysis of 62 selected genes in NLPHL by targeted ultra-deep sequencing revealed three novel highly recurrently mutated genes (each mutated in ~50% of cases), that is, DUSP2, SGK1 and JUNB. SGK1 was expressed in the LP cells of primary NLPHL cases and in the NLPHL cell line DEV. Administration of an SGK1 inhibitor induced apoptosis in the NLPHL cell line DEV and the DLBCL cell line Farage, suggesting a pathogenetic role of SGK1 in the LP and DLBCL cells. In summary, the present study identifies SGK1, DUSP2 and JUNB as novel key players in the pathogenesis of NLPHL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Saarinen S, Pukkala E, Vahteristo P, Makinen MJ, Franssila K, Aaltonen LA . High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2013; 31: 938–943.

    Article  CAS  Google Scholar 

  2. Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000; 96: 1889–1899.

    CAS  Google Scholar 

  3. Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJ et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008; 205: 2251–2268.

    Article  CAS  Google Scholar 

  4. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17: 776–783.

    Article  CAS  Google Scholar 

  5. Hansmann ML, Stein H, Fellbaum C, Hui PK, Parwaresch MR, Lennert K . Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol 1989; 20: 1169–1175.

    Article  CAS  Google Scholar 

  6. Küppers R, Engert A, Hansmann ML . Hodgkin lymphoma. J Clin Invest 2012; 122: 3439–3447.

    Article  Google Scholar 

  7. Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA . Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27: 1346–1356.

    Article  Google Scholar 

  8. Hartmann S, Eichenauer DA, Plutschow A, Mottok A, Bob R, Koch K et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013; 122: 4246–4252.

    Article  CAS  Google Scholar 

  9. Boudova L, Torlakovic E, Delabie J, Reimer P, Pfistner B, Wiedenmann S et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003; 102: 3753–3758.

    Article  CAS  Google Scholar 

  10. Eichenauer DA, Engert A . Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma. Eur J Haematol 2014; 93: 1–8.

    Article  CAS  Google Scholar 

  11. Hartmann S, Martin-Subero JI, Gesk S, Hüsken J, Giefing M, Nagel I et al. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica 2008; 93: 1318–1326.

    Article  CAS  Google Scholar 

  12. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206: 981–989.

    Article  CAS  Google Scholar 

  13. Mottok A, Renne C, Willenbrock K, Hansmann ML, Brauninger A . Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 2007; 110: 3387–3390.

    Article  CAS  Google Scholar 

  14. Wlodarska I, Nooyen P, Maes B, Martin-Subero JI, Siebert R, Pauwels P et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 2003; 101: 706–710.

    Article  CAS  Google Scholar 

  15. Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116: 631–639.

    Article  Google Scholar 

  16. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ . Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010; 28: 793–799.

    Article  Google Scholar 

  17. Hartmann S, Eray M, Doring C, Lehtinen T, Brunnberg U, Kujala P et al. Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology. BMC Cancer 2014; 14: 332.

    Article  Google Scholar 

  18. Küppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 1994; 91: 10962–10966.

    Article  Google Scholar 

  19. Küppers R, Dührsen U, Hansmann ML . Pathogenesis, diagnosis, and treatment of composite lymphomas. Lancet Oncol 2014; 15: e435–e446.

    Article  Google Scholar 

  20. Ame JC, Spenlehauer C, de Murcia G . The PARP superfamily. Bioessays 2004; 26: 882–893.

    Article  CAS  Google Scholar 

  21. Lang R, Hammer M, Mages J . DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol 2006; 177: 7497–7504.

    Article  CAS  Google Scholar 

  22. Ranjan R, Deng J, Chung S, Lee YG, Park GY, Xiao L et al. The transcription factor nuclear factor of activated T cells c3 modulates the function of macrophages in sepsis. J Innate Immun 2014; 6: 754–764.

    Article  CAS  Google Scholar 

  23. Goncalves A, Burckstummer T, Dixit E, Scheicher R, Górna MW, Karayel E et al. Functional dissection of the TBK1 molecular network. PLoS One 2011; 6: e23971.

    Article  CAS  Google Scholar 

  24. George A, Morse HC 3rd, Justice MJ . The homeobox gene Hex induces T-cell-derived lymphomas when overexpressed in hematopoietic precursor cells. Oncogene 2003; 22: 6764–6773.

    Article  CAS  Google Scholar 

  25. Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M et al. JunB is a gatekeeper for B-lymphoid leukemia. Oncogene 2007; 26: 4863–4871.

    Article  CAS  Google Scholar 

  26. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471: 377–381.

    Article  CAS  Google Scholar 

  27. Schneider M, Schneider S, Zuhlke-Jenisch R, Klapper W, Sundström C, Hartmann S et al. Alterations of the CD58 gene in classical Hodgkin lymphoma. Genes Chromosomes Cancer 2015; 54: 638–645.

    Article  CAS  Google Scholar 

  28. Reichel J, Chadburn A, Rubinstein PG, Giulino-Roth L, Tam W, Liu Y et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015; 125: 1061–1072.

    Article  CAS  Google Scholar 

  29. Liso A, Capello D, Marafioti T, Tiacci E, Cerri M, Distler V et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood 2006; 108: 1013–1020.

    Article  CAS  Google Scholar 

  30. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21: 4104–4113.

    Article  CAS  Google Scholar 

  31. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V . (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 2006; 86: 1151–1178.

    Article  CAS  Google Scholar 

  32. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 1398–1403.

    Article  CAS  Google Scholar 

  33. Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB et al. Genetics of follicular lymphoma transformation. Cell Rep 2014; 6: 130–140.

    Article  CAS  Google Scholar 

  34. Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 2013; 210: 2273–2288.

    Article  CAS  Google Scholar 

  35. Braeuninger A, Küppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML . Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA 1997; 94: 9337–9342.

    Article  CAS  Google Scholar 

  36. Oeschger S, Bräuninger A, Küppers R, Hansmann ML . Tumor cell dissemination in follicular lymphoma. Blood 2002; 99: 2192–2198.

    Article  CAS  Google Scholar 

  37. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879–3884.

    Article  CAS  Google Scholar 

  38. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298–303.

    Article  CAS  Google Scholar 

  39. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189–195.

    Article  CAS  Google Scholar 

  40. Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148: 59–71.

    Article  CAS  Google Scholar 

  41. Qian J, Wang Q, Dose M, Stütz AM, Zichner T, Weischenfeldt J et al. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell 2014; 159: 1524–1537.

    Article  CAS  Google Scholar 

  42. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013; 45: 970–976.

    Article  CAS  Google Scholar 

  43. Szremska AP, Kenner L, Weisz E, Ott RG, Passegué E, Artwohl M et al. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 2003; 102: 4159–4165.

    Article  CAS  Google Scholar 

  44. Schif B, Lennerz JK, Kohler CW, Bentink S, Kreuz M, Melzner I et al. SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients. Oncotarget 2013; 4: 35–47.

    Article  Google Scholar 

  45. Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K . The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 1996; 271: 6497–6501.

    Article  CAS  Google Scholar 

  46. Leventaki V, Drakos E, Karanikou M, Psatha K, Lin P, Schlette E et al. c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma. Hum Pathol 2014; 45: 565–572.

    Article  CAS  Google Scholar 

  47. Hall BA, Kim TY, Skor MN, Conzen SD . Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression. Breast Cancer Res Treat 2012; 135: 469–479.

    Article  CAS  Google Scholar 

  48. Towhid ST, Liu GL, Ackermann TF, Beier N, Scholz W, Fuchß T et al. Inhibition of colonic tumor growth by the selective SGK inhibitor EMD638683. Cell Physiol Biochem 2013; 32: 838–848.

    Article  CAS  Google Scholar 

  49. O'Neill D, Jones D, Wade M, Grey J, Nakjang S, Guo W et al. Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget 2015; 6: 26029–26040.

    Google Scholar 

  50. Brickley DR, Agyeman AS, Kopp RF, Hall BA, Harbeck MC, Belova L et al. Serum- and glucocorticoid-induced protein kinase 1 (SGK1) is regulated by store-operated Ca2+ entry and mediates cytoprotection against necrotic cell death. J Biol Chem 2013; 288: 32708–32719.

    Article  CAS  Google Scholar 

  51. Zhang L, Cui R, Cheng X, Du J . Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase. Cancer Res 2005; 65: 457–464.

    CAS  Google Scholar 

  52. Amato R, D'Antona L, Porciatti G, Agosti V, Menniti M, Rinaldo C et al. Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. J Mol Med (Berl) 2009; 87: 1221–1239.

    Article  CAS  Google Scholar 

  53. Fagerli UM, Ullrich K, Stuhmer T, Holien T, Köchert K, Holt RU et al. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells. Oncogene 2011; 30: 3198–3206.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Sabine Albrecht, Smaro Soworka, Ottilja Buhr, Ekaterini Hadzoglou, Susanne Hansen, Elena Hartung, Julia Bein, Maria Kemele, Christina Jakobus, Ralf Lieberz, Christiane Wenk and the EMBL GeneCore sequencing team and the EMBL IT unit for excellent technical assistance. We thank Dr Frederike Schmid, Dr Friederike Schwartz and Dr Marc Seifert for helpful discussions. This project was supported by the Deutsche Forschungsgemeinschaft (grant HA6145/1-2). M-LH, CD and SN were supported by the Kassel Stiftung. RK and M-LH were supported by the German Cancer Consortium (DKTK), the BMBF (01KU1002F; International Cancer Genome consortium, ICGC) and the Wilhelm Sander Foundation (2014.136.1).

Author contributions

SH was involved in the study design, performed the research, analysis and interpretation of data and wrote the manuscript; BS, AL, MW, LF, CW, LT and BR performed the research, analysis and interpretation of data; CD and TR performed the biostatistical analysis and interpretation of NGS data; UB, MV and VB contributed the essential material and were involved in the interpretation of data; MP, RK and SN performed the analysis and interpretation of data, and were involved in drafting the manuscript; M-LH was involved in the study design, interpretation of data and drafting the manuscript.

Author information

Author notes

  1. S Newrzela and M-L Hansmann: These authors contributed equally to this work.

Authors and Affiliations

  1. Dr Senckenberg Institute of Pathology, Goethe University Hospital Frankfurt, Frankfurt, Germany

    S Hartmann, B Schuhmacher, L Fuller, C Döring, C Weiser, B Rengstl, S Newrzela & M-L Hansmann

  2. GeneCore, European Molecular Biology Laboratory, Heidelberg, Germany

    T Rausch & V Benes

  3. Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany

    T Rausch

  4. Institute of Cell Biology (Cancer Research), Faculty of Medicine, University of Duisburg-Essen, Essen, Germany

    M Weniger, A Lollies & R Küppers

  5. José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany

    L Thurner & M Pfreundschuh

  6. Department of Internal Medicine 2, Hospital of The J. W. Goethe University, Frankfurt, Germany

    U Brunnberg

  7. Department of Pathology, Tampere University Hospital, University of Tampere, Tampere, Finland

    M Vornanen

  8. The German Cancer Consortium (DKTK), Essen, Germany

    R Küppers

Authors
  1. S Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Schuhmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Rausch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Fuller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Döring
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Weniger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Lollies
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Weiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Thurner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B Rengstl
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. U Brunnberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Vornanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M Pfreundschuh
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. V Benes
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. R Küppers
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Newrzela
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M-L Hansmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Hartmann.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hartmann, S., Schuhmacher, B., Rausch, T. et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia 30, 844–853 (2016). https://doi.org/10.1038/leu.2015.328

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.328

This article is cited by

Search

Advanced search

Quick links